Clinical Trials Logo

Filter by:
NCT ID: NCT06423690 Not yet recruiting - Lung Cancer Clinical Trials

First in Human Study for the Assessment of Safety and Initial Performance of the EAS1 System

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

A Prospective, open label, multi center, single arm, First in Human study to assess the safety and initial performance of EAS1 system for Irreversible Electroporation (IRE) ablation of lung cancer in subjects eligible for tumor resection

NCT ID: NCT06423651 Recruiting - Schizophrenia Clinical Trials

Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders

CR+MCTp
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery. The main questions it aims to answer are: - Does combined REHACOP + MCT therapy increase the clinical recovery in persons with nonaffective psychotic disorder (compared to MCT alone)? - What is the impact of combined REHACOP + MCT therapy compared to MCT therapy alone on personal/psychological recovery, cognitive biases, and social cognition, taking gender differences into account? - What is the durability of the effects of combined REHACOP + MCT therapy compared to MCT therapy alone on clinical recovery, personal recovery, cognitive biases, and social cognition in the long term? Researchers will compare REHACOP+MCT therapy to MCT alone to see if there are differences in personal/psychological recovery. Participants will: - Participate in Metacognitive Training or in combined REHACOP + Metacognitive training therapy. - Do 8 weekly sessions of 45-60 minutes (MCT group). - Do 12 weekly sessions of 45-60 minutes (RECHACOP+MCT group). - Visit the clinic for checkups and tests. - Answer self-administered tests.

NCT ID: NCT06423196 Not yet recruiting - Clinical trials for Sports Physical Therapy

Upper Limb Blood Flow Restriction in Handball Players

Start date: May 19, 2024
Phase: N/A
Study type: Interventional

Introduction. Blood flow restriction therapy involves the use of an occlusion cuff placed over an extremity resulting in a partial reduction of arterial blood flow and total restriction of venous return. Objectives. To analyse the efficacy of a physiotherapy intervention using blood flow restriction in improving upper limb strength in adult handball players. Methods. Randomised, single-blind, clinical study. 20 athletes will be recruited and randomly assigned to the experimental and control groups. The intervention of the experimental group will consist of performing an exercise protocol after blood flow restriction. The intervention period will last 4 weeks, with a periodicity of 2 weekly sessions of 30 minutes each. The primary variable will be the strength of the triceps, epicondyle and epitrochlear musculature (pressure hand dynamometer). The secondary variable will be the muscle activation of this musculature (surface electromyography).

NCT ID: NCT06423157 Not yet recruiting - Clinical trials for Sports Physical Therapy

Plyometric and Stability Exercise Protocol in Female Basketball Players

Start date: May 19, 2024
Phase: N/A
Study type: Interventional

Introduction. Basketball is a high intensity intermittent sport, requiring jumping, running, accelerations and decelerations with changes of direction and lateral movements. Plyometric exercises are a training technique that consists of a cycle of muscle stretching and shortening in which the energy stored in the eccentric phase (lengthening) is released facilitating the production of maximum power in the concentric phase (shortening). Objective. To analyse the efficacy of a physiotherapy intervention through a protocol of plyometric and stability exercises in the improvement of vertical jump, stability, flexibility and agility in federated female basketball players. The primary variable will be the vertical jump (My jump 2.0). Secondary variables will be stability (Y balance test), flexibility (Sit and Reach) and agility (T-Test). Methods. Controlled, single-blind clinical study. 20 athletes will be randomised to the experimental and control groups. The intervention of the experimental group will consist of a protocol using plyometric and stability exercises. The athletes included in the control group will not perform any intervention and will continue with their usual routine. The intervention period will last 6 weeks, with a periodicity of 2 weekly sessions of 20 minutes each.

NCT ID: NCT06422975 Not yet recruiting - Shock Clinical Trials

Registry of Patients in Shock Treated With Vasopressin

Start date: June 2024
Phase:
Study type: Observational [Patient Registry]

Arginine-vasopressin (AVP) is a non-catecholaminergic hormone produced in the hypothalamus and released into the circulation via the neurohypophysis. It has different actions depending on the receptors through which it acts: V1 (vasoconstriction, platelet aggregation, efferent arteriole constriction of the renal glomerulus, glycogenolysis); V2 (water reabsorption, release of von Willebrand factor and factor VIII); V3 (increased cortisol and insulin). Septic shock is the most common cause of vasoplegic shock and its management includes control of the focus, early antibiotic therapy, volume resuscitation, vasopressor therapy, support of various organ dysfunctions, as well as monitoring and follow-up. The Surviving Sepsis Campaign (a global initiative to improve sepsis management) recommends noradrenaline as the first line of vasopressor therapy and early addition of AVP as a second line rather than further up-titration of noradrenaline when signs of hypoperfusion persist, through its action primarily on V1. The rationale for its use in septic shock would be: - endogenous vasopressin deficiency present in septic shock; - as a catecholamine-sparing strategy, reducing the side effects of catecholamines; - its potential nephroprotective effect; - its use should be early. The uncertainties surrounding the use of AVP in septic shock and other types of shock are many, hence the need for this registry.

NCT ID: NCT06422741 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers

CIRCAFENOL
Start date: May 2024
Phase: N/A
Study type: Interventional

The physiological processes of the body present daily oscillations called circadian rhythm. The circadian rhythm is essential for maintaining the vital functions of organisms, intervening directly and indirectly in a multitude of key processes, such as hormone secretion, cycles of activity and rest throughout the day, body temperature, the metabolism or absorption, processing and detoxification of nutrients. There are factors such as certain work schedules, prolonged exposure to screens, certain eating patterns or social jetlag, which have a negative impact on the circadian rhythm, causing its disruption and favoring the appearance of health alterations. Thus, there is evidence that associates night shift work with a higher incidence of risk factors for developing metabolic syndrome and cardiovascular diseases, including obesity, elevated blood levels of glucose, triglycerides, and low-density lipoprotein cholesterol (LDL-C), as well as lower levels of high-density lipoprotein cholesterol (HDL-C). In addition, disorders in the sleep cycle are associated with the development of hypertension and type 2 diabetes. Several previous studies show that a grape seed proanthocyanidin extract (GSPE) has beneficial effects on different parameters by restoring the circadian rhythm.

NCT ID: NCT06422351 Not yet recruiting - Clinical trials for Pyruvate Kinase Deficiency

Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency

Start date: August 2024
Phase: Phase 2
Study type: Interventional

This is an open-label Phase II trial to evaluate the efficacy of a hematopoietic cell-based gene therapy for patients with Pyruvate Kinase Deficiency (PKD).

NCT ID: NCT06422221 Not yet recruiting - Bacteremia Clinical Trials

An Oral Doxycycline Regimen to Prevent Bacteremia Following Dental Procedures

Start date: July 15, 2024
Phase: Phase 4
Study type: Interventional

Although controversy exists regarding the efficacy of antibiotic prophylaxis for patients at risk of infective endocarditis, expert committees continue to publish recommendations for antibiotic prophylactic regimens. The last American Heart Association (AHA) and European Society of Cardiology (ESC) guidelines include several important changes, highlighting that clindamycin (CLI) is no longer recommended as an alternative to amoxicillin in those allergic to penicillin. This new project aims to evaluate the effectiveness of oral doxycycline in preventing post-dental extraction bloodstream infection.

NCT ID: NCT06421467 Not yet recruiting - Diabetes Clinical Trials

Insulin Injection Practices in Spain

Start date: July 2024
Phase:
Study type: Observational

In this era of pharmaceutical and technological advancements, gaining insights into prevalent insulin administration practices under real-life conditions becomes pivotal for healthcare professionals. The investigators aim to explore insulin injection habits through an online survey among a broad, unselected group of participants with type 1 and type 2 diabetes undergoing daily prandial and/or basal insulin treatment. Eligible participants will access and complete the survey at their convenience after providing online informed consent within the study period

NCT ID: NCT06421402 Enrolling by invitation - COPD Clinical Trials

K-HEALTH in AIR - Barcelona Pilot - Cohort

Start date: October 13, 2023
Phase:
Study type: Observational [Patient Registry]

The study protocol is part of the European (EU) project "Knowledge for improving indoor AIR quality and HEALTH" (K-HEALTHinAIR, 2022-2026 - registry 101057693), which focuses on enhancing our understanding of how poor indoor air quality (IAQ) affects human health. Specifically, the project aims to identify IAQ determinants of adverse health events and to explore the development of cost-effective strategies for the precise monitoring and improvement, of IAQ across Europe. With the current study protocol, the Barcelona Pilot, at the Integrated Health District of Barcelona-Esquerra (AISBE, 520 k citizens), is conducting a cohort study over a two-year period (January 2024 to December 2025) to explore the relationships between IAQ (assessment of chemical pollutants in patients' homes) and health status (acute episodes) in multimorbid patients with chronic respiratory diseases (asthma and Chronic Obstructive Pulmonary Disease - COPD) over a two-year period. The protocol investigates the effectiveness of customized interventions across four critical areas: i) Advanced lung function testing, ii) Continuous IAQ monitoring, iii) Advanced digital support to innovative clinical processes, and iv) Predictive modeling for early identification and management of exacerbations. The ultimate objective is to design and evaluate an innovative integrated care service aiming at enhancing both IAQ and the management of multimorbid patients with chronic obstructive respiratory diseases, with focus on COPD and severe asthma.